NYSE:BLCO

Bausch + Lomb (BLCO) Stock Price, News & Analysis

Bausch + Lomb logo
$19.38 -1.31 (-6.33%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$19.39 +0.01 (+0.03%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Bausch + Lomb Stock (NYSE:BLCO)

Advanced

Key Stats

Today's Range
$19.30
▼
$20.50
50-Day Range
$15.83
▼
$21.35
52-Week Range
$14.53
▼
$21.40
Volume
871,551 shs
Average Volume
1.06 million shs
Market Capitalization
$6.94 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.08
Consensus Rating
Hold

Company Overview

Bausch + Lomb Corporation is an eye-health company that develops, manufactures and markets products for consumers, eye-care professionals and surgical teams. Its business spans vision care, pharmaceuticals and surgical devices.

Its products include contact lenses and lens-care solutions, as well as eye-health medicines and nutritional supplements. The company also supplies equipment, technologies and related products used in eye surgery and other ophthalmic procedures.

Founded in Rochester, New York, in 1853 by John Jacob Bausch and Henry Lomb, the company serves customers in more than 100 countries. Bausch + Lomb became an independent publicly traded company in 2022 after separating from Bausch Health Companies.

AI Generated. May Contain Errors.

Bausch + Lomb Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
68th Percentile Overall Score

BLCO MarketRank™: 
3.421857619575 of 5 stars

Bausch + Lomb scored higher than 68% of companies evaluated by MarketBeat, and ranked 245th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bausch + Lomb has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 1 strong buy rating, 5 buy ratings, 8 hold ratings, and 1 sell rating.

  • Upside/Downside

    The consensus price target for Bausch + Lomb is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Bausch + Lomb has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Bausch + Lomb's stock forecast and price target.
  • Earnings Growth

    Earnings for Bausch + Lomb are expected to grow by 24.47% in the coming year, from $0.94 to $1.17 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bausch + Lomb is -62.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bausch + Lomb is -62.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Bausch + Lomb has a PEG Ratio of 0.55. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Bausch + Lomb has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.74% of the float of Bausch + Lomb has been sold short.
  • Short Interest Ratio / Days to Cover

    Bausch + Lomb has a short interest ratio ("days to cover") of 2.28, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bausch + Lomb has recently increased by 1.87%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Bausch + Lomb does not currently pay a dividend.

  • Dividend Growth

    Bausch + Lomb does not have a long track record of dividend growth.

  • News Sentiment

    Bausch + Lomb has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Bausch + Lomb this week, compared to 5 articles on an average week.
  • Search Interest

    3 people have searched for BLCO on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bausch + Lomb insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,294,067.00 in company stock.

  • Percentage Held by Insiders

    1.45% of the stock of Bausch + Lomb is held by insiders.

  • Percentage Held by Institutions

    11.07% of the stock of Bausch + Lomb is held by institutions.

  • Read more about Bausch + Lomb's insider trading history.
Receive BLCO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch + Lomb and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BLCO Stock News Headlines

Why Bausch + Lomb shares are getting obliterated today
ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
Bausch + Lomb stock slips as eye pain drug misses endpoint
Bausch + Lomb eye-drop drug misses mid-stage study main goal
Bausch + Lomb (NYSE:BLCO) CAO Sells $2,294,067.20 in Stock
See More Headlines

BLCO Stock Analysis - Frequently Asked Questions

Bausch + Lomb's stock was trading at $17.07 at the beginning of the year. Since then, BLCO stock has increased by 13.5% and is now trading at $19.38.

Bausch + Lomb Corporation (NYSE:BLCO) posted its quarterly earnings data on Wednesday, October, 28th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.13. Bausch + Lomb's revenue for the quarter was up 7.3% compared to the same quarter last year.
Read the conference call transcript
.

Bausch + Lomb (BLCO) raised $788 million in an IPO on Friday, May 6th 2022. The company issued 35,000,000 shares at $21.00-$24.00 per share.

Top institutional investors of Bausch + Lomb include BROOKFIELD Corp ON (1.28%), BROOKFIELD Corp ON (1.28%), Beach Point Capital Management LP (0.10%) and Ballast Asset Management LP (0.06%). Insiders that own company stock include Brent L Saunders, Sam Eldessouky, A Robert D Bailey, Eschenbach Andrew C Von and Frederick Munsch.
View institutional ownership trends
.

Shares of BLCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bausch + Lomb investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Walmart (WMT), Alphabet (GOOG), Netflix (NFLX) and Alibaba Group (BABA).

Company Calendar

Last Earnings
10/28/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Supplies
Current Symbol
NYSE:BLCO
CIK
1860742
Fax
N/A
Employees
13,000
Year Founded
1853

Price Target and Rating

High Price Target
$27.00
Low Price Target
$16.00
Potential Upside/Downside
+8.8%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
15 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.31)
Trailing P/E Ratio
N/A
Forward P/E Ratio
16.56
P/E Growth
0.55
Net Income
-$360 million
Net Margins
-2.05%
Pretax Margin
-0.07%
Return on Equity
5.01%
Return on Assets
2.34%

Debt

Debt-to-Equity Ratio
0.78
Current Ratio
1.56
Quick Ratio
1.04

Sales & Book Value

Annual Sales
$5.10 billion
Price / Sales
1.36
Cash Flow
$1.55 per share
Price / Cash Flow
12.51
Book Value
$18.18 per share
Price / Book
1.07

Miscellaneous

Outstanding Shares
358,080,000
Free Float
352,887,000
Market Cap
$6.94 billion
Optionable
Optionable
Beta
0.52

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NYSE:BLCO) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners